主页 > 生命科学 >
【drug-news】BIO 产业新闻汇集 9/4
Pfizer agreed to team up with Medivation to develop and market Dimebon, a 25-year-old cold drug, as a treatment for Alzheimer's and Huntington's diseases. The ***aceutical firm could receive as much as $725 million from Pfizer, which is banking on Dimebon to replenish its pipeline. The Wall Street Journal (subscription required) (9/4) , San Francisco Chronicle (9/4)
Performance Management: The Future of Medical Device Manufacturing. In the face of competition, regulation and customer demands, Medical Device manufacturers must confront operational challenges that impact the top and bottom line. Click Here for a free white paper and learn how the leading companies leverage their best of breed systems for optimal productivity.
Health Care & Policy
BIO to seek increased FDA funding from next U.S. president
BIO President and CEO Jim Greenwood said the group is not endorsing a U.S. presidential candidate "because there's not such a great difference" between the two nominees, who both support embryonic stem cell research and other biotech efforts. BIO will instead urge the next president to raise the FDA's budget to hasten the evaluation of drugs awaiting approval, Greenwood said. Boston Herald (9/4)
Research of brain protein may lead to fertility treatments
Scientists working on female mice found that signaling between kisspeptin -- a brain protein that plays a role in activating puberty -- and its cell receptor GPR54 triggered ovulation by kick-starting gonadotrophin-releasing hormone neurons. "Targeting drugs to this chemical switch to make it work properly may help some people who are infertile, while finding compounds that can block this switch could lead to new contraceptives," the lead researcher said. Reuters (9/3)
Study suggests genetic link between low birth weight, Type 2 diabetes
A study suggests that common genes may be the cause of both low birth weight and Type 2 diabetes susceptibility in adulthood. The study, which involved more than 18,000 fraternal and identical twins in Sweden, indicates that genetic factors may be important in understanding the relationship between birth weight and diabetes, one of the researchers said. Yahoo!/Reuters (9/3)
Company & Financial News
HHS taps Emergent BioSolutions to develop anthrax treatment
Emergent BioSolutions landed a four-year, $24.3 million contract with HHS to further develop AVP-21D9, an antibody-based anthrax drug. The funding, which will be used to conduct human testing and boost production capacity, "underscores the U.S. government's commitment to a multiprong approach in responding to the threat of bioterrorism," an Emergent official said. Bloomberg (9/3) , American City Business Journals/Washington, D.C. (9/3)
Czech city moves to become international biotech hub
Czech Republic officials plan to transform the city of Brno into a modern biotech hub by boosting education and infrastructure to attract companies. Brno's partnership with the U.S.-based Mayo Clinic will help the country, which hosts about 60 biotech firms, become "a clinical research center" in Europe, a former government adviser said. Yahoo!/Reuters (9/3)
Industry Deals
Opexa partners with foundation to study multiple sclerosis biomarkers
Opexa Therapeutics has entered into a collaborative agreement with the Myelin Repair Foundation to detect biomarkers in multiple sclerosis. Opexa hopes that the research will bolster the development of diagnostics and its Tovaxin -- a cellular vaccine undergoing clinical trials -- for MS patients. American City Business Journals/Houston (9/3)
Azaya licenses liposome technology for cancer treatment
Azaya Therapeutics has entered into a licensing agreement with the University of Texas Health Science Center at San Antonio to gain access to a radiation-infused liposome technology that can improve the treatment of head and neck cancers. Azaya plans to conduct early-stage trials of the technology to explore its potential to shrink tumors without risking collateral tissue damage or cancer recurrence. American City Business Journals/San Antonio (9/3)
Food & Agriculture
Officials: EU to allow imports of Bayer's biotech soybeans
The European Commission is expected next week to permit the importation of Bayer CropScience's biotech soybeans for use in food production and animal feed, officials said. The approval of the A2704-12 soybean -- designed to resist glufosinate herbicides -- will help address an animal-feed shortage and may prompt the EC to avoid recommending a limit for amounts of unauthorized biotech material in imports, officials said. Reuters (9/3)
Expert: Japan, Europe must embrace biotech wheat
Japan and European countries must accept and help educate the public about biotech wheat to fight food shortages and rising food prices in the developing world, said Thomas Lumpkin, head of the International Maize and Wheat Improvement Center. "By denying them this technology, you are keeping them hungry, [and] they are dying," he said. Reuters (9/3) 拜读下~~~ [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-07 15:46
医学,生命科学网